These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
Portfolio Pulse from Lisa Levin
Century Therapeutics (NASDAQ:IPSC) reported weaker-than-expected Q2 results, with a loss of 56 cents per share and sales of $99,000, missing estimates. Following the announcement, Chardan Capital, HC Wainwright & Co., and EF Hutton revised their price targets for the company's shares.
August 10, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Century Therapeutics reported weaker-than-expected Q2 results, leading to a decrease in its share price and revised price targets by several analysts.
Century Therapeutics' weaker-than-expected Q2 results have led to a decrease in its share price. Additionally, several analysts have revised their price targets for the company's shares, indicating a potential negative impact on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100